CompanyGraph
Beijing Bohui Innovation Technology Co., Ltd.
300318 · SZSE · China
bohui-tech.comFinancials as of FY2025
At a glance
- Depends onUpstream position: supplies 6 industries, depends on 3
- PositionCurrent ratio is 0.88×, lower than 95% of its Biotechnology peers (median 5.71×)
- FinancialsAltman Z-Score 1.09: distress zone
Sign in to view price data.
Sign inThe reported statements, read against the company's own industry.
Financials view
Market Capitalization
3.99BCNY596.08M · vs all stocks (USD)
Revenue (TTM)
816.14MCNY121.78M · vs all stocks (USD)
Profit Margin
-10.89%vs Biotechnology peers
Beta
0.1000xvs all stocks
52-Week Change
-14.06%vs all stocks
Market Capitalization
3.99BCNY596.08M · vs all stocks (USD)
Enterprise Value
5.66BCNY844.75M · vs all stocks (USD)
Price to Sales (TTM)
4.89xvs Biotechnology peers
Price to Book (MRQ)
3.14xvs Biotechnology peers
Enterprise to Revenue
6.94xvs Biotechnology peers
Enterprise to EBITDA
175.71xvs Biotechnology peers
Gross Margin
35.61%vs Biotechnology peers
Profit Margin
-10.89%vs Biotechnology peers
Operating Margin
-9.77%vs Biotechnology peers
Return on Assets (TTM)
-0.81%vs Biotechnology peers
Return on Equity (TTM)
-7.65%vs Biotechnology peers
Revenue (TTM)
816.14MCNY121.78M · vs all stocks (USD)
Revenue per Share (TTM)
0.9980CNYUpdated Sep 20, 2026Quarterly Revenue Growth
1.70%vs Biotechnology peers
Gross Profit (TTM)
260.28MCNY38.84M · vs all stocks (USD)
EBITDA (TTM)
51.19MCNY7.64M · vs all stocks (USD)
Net Income (TTM)
-88.84MCNY-13.26M · vs all stocks (USD)
Operating Cash Flow (TTM)
-121.20MCNY-18.09M · vs all stocks (USD)
Payout Ratio
0.00%vs Biotechnology peers
Minority Interest (Equity)
890.81MCNYFY2025 · Dec 31, 2025Revenue
824.58MCNYFY2025 · Dec 31, 2025Cost of Goods Sold
498.40MCNYFY2025 · Dec 31, 2025Gross Profit
326.17MCNYFY2025 · Dec 31, 2025Operating Income
6.95MCNY1.04M · vs all stocks (USD)
Pre-tax Income
-171.31MCNYFY2025 · Dec 31, 2025Income Tax Expense
694.86KCNYFY2025 · Dec 31, 2025Net Income
-172.01MCNYFY2025 · Dec 31, 2025EBIT
-137.89MCNYFY2025 · Dec 31, 2025EBITDA (Income Statement)
51.19MCNYFY2025 · Dec 31, 2025Research & Development
64.92MCNYFY2025 · Dec 31, 2025Selling, General & Administrative
82.62MCNYFY2025 · Dec 31, 2025Other Operating Expenses
15.63MCNYFY2025 · Dec 31, 2025Non-operating Interest Income
1.98MCNYFY2025 · Dec 31, 2025Non-operating Interest Expense
33.43MCNYFY2025 · Dec 31, 2025EPS (Basic)
-0.1125CNYFY2025 · Dec 31, 2025EPS (Diluted)
-0.1125CNYFY2025 · Dec 31, 2025Basic Shares Outstanding
817.10MSharesFY2025 · Dec 31, 2025Diluted Shares Outstanding
817.10MSharesFY2025 · Dec 31, 2025Net Income from Continuing Operations
-172.01MCNYFY2025 · Dec 31, 2025Minority Interests (P&L)
80.08MCNYFY2025 · Dec 31, 2025Preferred Stock Dividends
0.00CNYFY2025 · Dec 31, 2025Operating Cash Flow
-347.79MCNYFY2025 · Dec 31, 2025Free Cash Flow
-474.42MCNYFY2025 · Dec 31, 2025Cash & Cash Equivalents (End of Period)
103.33MCNYFY2025 · Dec 31, 2025Starting Profit (CF Statement)
-172.01MCNYFY2025 · Dec 31, 2025Other Non-cash Items
46.41MCNYFY2025 · Dec 31, 2025Change in Accounts Receivable (CF)
-52.78MCNYFY2025 · Dec 31, 2025Change in Other Assets/Liabilities
-169.41MCNYFY2025 · Dec 31, 2025Capital Expenditures
-126.63MCNYFY2025 · Dec 31, 2025Purchase of Investments
-15.95MCNYFY2025 · Dec 31, 2025Sale of Investments
17.13MCNYFY2025 · Dec 31, 2025Other Investing Activity
46.41KCNYFY2025 · Dec 31, 2025Net Investing Cash Flow
-125.41MCNYFY2025 · Dec 31, 2025Long-term Debt Issuance
1.00BCNYFY2025 · Dec 31, 2025Long-term Debt Payments
-921.24MCNYFY2025 · Dec 31, 2025Common Dividends Paid
-31.38MCNYFY2025 · Dec 31, 2025Other Financing Charges
257.63MCNYFY2025 · Dec 31, 2025Net Financing Cash Flow
308.21MCNYFY2025 · Dec 31, 2025Shares Outstanding
816.90MSharesUpdated Sep 20, 2026Float Shares
317.28MSharesUpdated Sep 20, 2026% Held by Insiders
61.29%vs all stocks
% Held by Institutions
0.44%vs all stocks
Total Cash (MRQ)
134.32MCNY20.04M · vs all stocks (USD)
Total Cash per Share (MRQ)
0.1640CNYUpdated Sep 20, 2026Total Debt (MRQ)
923.68MCNY137.83M · vs all stocks (USD)
Total Debt to Equity (MRQ)
0.4299xvs Biotechnology peers
Current Ratio (MRQ)
0.8820xvs Biotechnology peers
Book Value per Share (MRQ)
1.56CNYUpdated Sep 20, 2026Total Assets
4.30BCNY642.28M · vs all stocks (USD)
Total Current Assets
1.43BCNYFY2025 · Dec 31, 2025Total Liabilities
2.13BCNYFY2025 · Dec 31, 2025Total Non-current Assets
2.88BCNYFY2025 · Dec 31, 2025Total Non-current Liabilities
597.48MCNYFY2025 · Dec 31, 2025Total Current Liabilities
1.53BCNYFY2025 · Dec 31, 2025Cash
101.11MCNYFY2025 · Dec 31, 2025Cash Equivalents
20.72MCNYFY2025 · Dec 31, 2025Cash & Cash Equivalents
121.83MCNYFY2025 · Dec 31, 2025Accounts Receivable
89.75MCNYFY2025 · Dec 31, 2025Inventory
1.14BCNYFY2025 · Dec 31, 2025Accounts Payable
220.40MCNYFY2025 · Dec 31, 2025Short-term Debt
654.81MCNYFY2025 · Dec 31, 2025Other Current Liabilities
5.13MCNYFY2025 · Dec 31, 2025Long-term Debt
471.94MCNYFY2025 · Dec 31, 2025Other Non-current Liabilities
2.54MCNYFY2025 · Dec 31, 2025Common Stock (Book)
816.90MCNYFY2025 · Dec 31, 2025Retained Earnings
-291.21MCNYFY2025 · Dec 31, 2025Total Shareholders' Equity
2.18BCNY324.70M · vs all stocks (USD)
52-Week Low
4.06CNYUpdated Sep 20, 202652-Week High
8.63CNYUpdated Sep 20, 202652-Week Change
-14.06%vs all stocks
Beta
0.1000xvs all stocks
50-Day MA
4.92CNYUpdated Sep 20, 2026200-Day MA
5.58CNYUpdated Sep 20, 2026Avg 10-Day Volume
6.01MSharesUpdated Sep 20, 2026Avg 30-Day Volume
10.04MSharesUpdated Sep 20, 2026Diluted EPS (TTM)
-0.1100CNYUpdated Sep 20, 2026Shared structure with peers — never a ranking.
Relationships view
Structural observations derived from financial data, industry benchmarks, and supply chain position.
Peer Positioning
Current ratio is 0.88×, lower than 95% of its Biotechnology peers (median 5.71×)Significant
Current ratio: 0.88Industry median: 5.71Industry P5: 1.02Peers compared: 260
Financial Health
Altman Z-Score 1.09: distress zoneCritical
Altman Z-Score: 1.09
Supply Chain
Upstream position: supplies 6 industries, depends on 3Notable
Outgoing: 6.00Incoming: 3.00
Companies that share the same coordination system — how they create, deliver, or capture value.
Shenzhen Neptunus Bioengineering Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Valneva SE
Tier 1ProductionApproval-Gated PipelineRuleRisk
Altimmune, Inc.
Tier 1ProductionApproval-Gated PipelineRule
Genfit S.A.
Tier 1ProductionApproval-Gated PipelineRuleRisk
Jinling Pharmaceutical Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Gkht Medical Technology Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRule
SS Innovations International, Inc.
Tier 1ProductionApproval-Gated PipelineRule
Shandong Wohua Pharmaceutical Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRuleFlow
Phathom Pharmaceuticals Inc.
Tier 1ProductionApproval-Gated PipelineRule
Hefei Lifeon Pharmaceutical Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRuleFlow